LivaNova PLC (LIVN) shares surged 10.64% in pre-market trading on Wednesday following the release of better-than-expected first-quarter 2025 results, raised full-year guidance, and positive clinical data for its sleep apnea treatment.
The medical technology company reported Q1 revenue of $316.9 million, surpassing the IBES estimate of $302.3 million. Adjusted earnings per share came in at $0.88, significantly beating the expected $0.76. LivaNova's strong performance was driven by high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion.
In light of the robust results, LivaNova raised its full-year 2025 revenue growth guidance to 6.0% to 7.0% on a constant-currency basis, up from the previous range of 5.0% to 6.0%. The company also announced positive 12-month data from its OSPREY clinical study for moderate to severe obstructive sleep apnea, demonstrating strong response and durability of therapy. The study showed an overall responder rate of 65% and a 68% reduction in both the median Apnea-Hypopnea Index and Oxygen Desaturation Index, potentially opening up new growth opportunities for LivaNova in the sleep apnea market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.